# EN｜How to Read the “Map of Probability” Called Inheritance: Five Branch Points Across BRCA, Family History, and Preventive Choices
In 2013, when a world-famous actress announced that she had had both breasts removed as a preventive measure, the world shared a single question alongside its surprise: “Why, when she didn’t have cancer?” The genetic test she had taken revealed an inborn change in a gene (BRCA1). It was, in effect, a “map of probability”—one that said she faced a very high chance of developing breast or ovarian cancer in the future.
Most breast cancers arise without any connection to inheritance, from aging and chance changes in cells (the nature of risk was covered in Vol.2). But roughly 5–10% are “hereditary,” strongly tied to an inborn genetic change passed down from a parent. This installment walks through how to read that map—what the BRCA genes are, how to make sense of family history, who should be tested, and what can be done “once you know you’re at high risk”—answering, head-on, the worries of patients and their families. Without alarm, but without easy reassurance either, the aim is to support people “correctly,” in the language of probability and biology.
Branch Point 1: Is “Lots of Cancer in the Family” a Sign of Inheritance?
Let’s clear up one misunderstanding first. “A relative had cancer” does not equal “I will inherit cancer.” Breast cancer is so common that, with no connection to inheritance at all, it is not unusual for several people in one family to be affected.
Even so, certain patterns are signs that inheritance may be involved. The classic ones:
- Onset at a young age (for example, before about 40–45)
- One person developing cancer in both breasts, or both breast and ovarian cancer
- A cluster of breast, ovarian, prostate, and pancreatic cancers in the family
- A case of male breast cancer
- Belonging to certain populations, such as people of Ashkenazi Jewish ancestry
These are clues that point to “hereditary breast and ovarian cancer syndrome (HBOC).” As the name says, HBOC is a predisposition in which breast and ovarian cancers tend to cluster in a family, and the BRCA genes sit at its center. Conversely, in the absence of such patterns, having one or two relatives with cancer is not cause for excessive worry. Family history is not “fate”; it is the first clue for deciding whether to “unfold the map and check.”
Branch Point 2: What BRCA Is—the “Repair Crew” Gene
The names BRCA1 and BRCA2 come from BReast CAncer. But these genes are not “genes that cause cancer.” Quite the opposite: their job is to repair damaged DNA—they are the cell’s “repair crew.” DNA in our cells is damaged every day, but when BRCA works properly, that damage is cleanly fixed.
When the blueprint for this repair crew carries an inborn change (a pathogenic variant), however, DNA damage goes unrepaired, other damage piles up over the years, and the path toward cancer becomes more likely. The crucial point here: “having a BRCA change” does not mean “you will definitely get cancer.” It is a matter of probability—being born with a constitution that is poor at repair—not a settled destiny.
Consider the actual figures. For a woman carrying a pathogenic BRCA1 variant, the lifetime risk of breast cancer is estimated, with some variation across studies, at roughly 55–72%, and for BRCA2 at roughly 45–69%. Compared with the general lifetime risk (a bit over one in ten in high-income countries), these are clearly elevated. Ovarian cancer risk rises too—around 40% for BRCA1 and 10–20% for BRCA2. BRCA1 is also known to tend toward earlier onset and toward triple-negative breast cancer (the “face with few targets” mentioned in Vol.5).
The numbers are heavy, but let me stress two things. First, these are cumulative figures spread across an entire lifetime; not everything happens early. Second, as we’ll see, knowing you are at high risk opens moves you can make—indeed, “knowing” becomes the greatest weapon.
The very width of these probability ranges carries meaning, too. “55–72%” is a range not only because studies vary but because penetrance—the share of people carrying a given gene change who actually go on to develop cancer—shifts with everything else around that person. Two people with the same BRCA1 change do not face identical risk if one comes from a family densely clustered with cancer and the other was found incidentally, with little family history. Lifestyle, hormonal environment, and even the polygenic background discussed in Branch Point 3 nudge that penetrance up or down. In other words, a BRCA figure is not a “fixed sentence” but a *range-bearing estimate* that gains its meaning only within a person’s own context. Rather than being frightened by a single average, the first step in reading the map of probability correctly is to work out, together with a specialist, where your own range actually lies.
One more step on how to read the numbers. The difference between “relative risk” and “absolute risk,” touched on in Vol.2, matters especially here. Hearing “BRCA1 raises breast cancer risk several-fold over the general population” is overwhelming, but that is a *lifetime* cumulative figure; the actual probability at, say, age 40 is far smaller. Risk accumulates gradually with age, so there is no need to receive it as “right now, perhaps tomorrow.” Moreover, even with the same BRCA1 change, the real probability varies with where the change sits and how cancer clusters within the family. This is exactly why it is meaningful to have a specialist translate the figures in light of your own family’s information, rather than applying an internet “average” directly to yourself. A probability becomes a guide to action only once it is translated into something personal.
Branch Point 3: Not BRCA Alone—Panel Testing and Polygenic Risk
The map of genetics has expanded greatly over the past decade. Genetic testing once meant examining BRCA1/2; now multigene panel testing, which checks many genes at once, is standard.
What’s worth knowing here is that “risk comes in degrees.”
- High-risk genes: BRCA1, BRCA2, PALB2 and others—several-fold (roughly 5–10×) the population risk.
- Moderate-risk genes: ATM, CHEK2 and others—risk around 2–2.5×, far less dramatic than the high-risk genes.
These “degrees” matter in practice. PALB2, for instance, was once seen as moderate-risk, but recent studies show its lifetime breast cancer risk can reach roughly 50–76%—a level rivaling BRCA2—so it is now treated as a high-risk gene, with intensified screening including MRI recommended from around age 30. Even among “cancer-related genes,” the weight assigned to each is not fixed; its standing is updated as research advances. That is precisely why it is essential to confirm, against the latest evidence, not only “which gene carried a change” but “which tier that gene is currently classified into.”
Moderate-risk genes are harder to handle: “a change was found” does not equal “operate now.” They must be judged together with age, family history, and other factors. This is exactly why the presence of a specialist who can accurately translate what a result means—a genetic counselor or clinical geneticist—becomes decisive.
A newer current still is the polygenic risk score (PRS). This method sums up the “individual quirks” of many genes, each of tiny effect, to quantify a person’s genetic baseline. Even without a single strong change like BRCA, the accumulation of such small differences can, in some people, push risk up to a level rivaling a moderate-risk gene—or, conversely, lower it. Intriguingly, a PRS can distinguish “relatively higher” from “relatively lower” risk even among BRCA carriers. In other words, within the single label “BRCA-positive” there are further gradations. Understanding of hereditary risk is evolving from a binary “yes/no” into a continuous map of “how much.”
Branch Point 4: Who Should Be Tested—and What “Waiting for the Result” Means
So who should undergo genetic testing? It is not recommended for everyone. Generally, candidates are those with any of the patterns listed in Branch Point 1—young onset, bilateral disease, co-occurring breast and ovarian cancer, multiple HBOC-related cancers in close relatives, male breast cancer, or certain population backgrounds. For people already diagnosed with breast cancer, testing is increasingly recommended in triple-negative or young-onset cases, and the result feeds directly into the person’s own treatment choices (such as PARP inhibitors, covered in Vol.17).
Where exactly that line is drawn has, in fact, been widening year by year. International guidelines have recently lowered the age threshold for recommending testing from “45 or younger” to “50 or younger,” and have broadened the family-history criteria as well. Behind this lie falling test costs and a recognition that the older criteria were missing a real fraction of carriers who should have been tested. Cast the net wider, though, and more people will encounter hard-to-interpret results such as the “variant of uncertain significance (VUS)” discussed below. The question of “whom to test” rests on a constant tug-of-war between catching fewer carriers by surprise and not alarming people with uncertain information. That is precisely why the entry point matters: rather than deciding on your own whether you qualify, the better path is to organize your family history and bring it to a specialist.
Ideally, the process begins with genetic counseling. The test uses a blood (or saliva) sample, and results take several weeks. The weight of that “waiting time” may be understood only by those who have lived it. But sorting out, in pre-test counseling, “what results are possible” and “what can be done in each case” steadies the heart during the wait.
Results fall broadly into three patterns: pathogenic variant present (positive), absent (negative), and a variant of uncertain significance (VUS)—a gray zone meaning “a change exists, but whether it relates to cancer is currently unknown.” A VUS is far from rare and is not a “bad result.” Many are later reclassified as benign through further research, and preventive surgery and the like should not be undertaken on the basis of a VUS alone. Here, too, the specialist’s role in translating the result correctly is pivotal.
There is one more point that is easily overlooked: the meaning of “negative” changes with the family’s situation. If a relative who developed cancer has already been found to be BRCA-positive, and you do not carry that same change, your negative result is genuine reassurance—”you did not inherit the family’s risk.” But if no one in the family has been tested, your negative result means only “no change was found in at least the genes examined”; it does not erase the family history itself. The same word “negative” can carry very different weight—another reason this subtlety should be read together with a specialist. Testing is not finished when the result arrives; it is complete only once it includes “how to fold that result into your life.”
Branch Point 5: After You Learn You’re High-Risk—Three Roads, and How to Choose
Learning you are high-risk does not leave you powerless. On the contrary, this is the realm where “knowing” becomes strength. There are three broad options.
① Intensify screening (surveillance). The least burdensome choice. High-risk people are advised to begin screening at an earlier age than usual and to combine mammography with breast MRI, at higher frequency and sensitivity. The strategy is not to “prevent” cancer but to “catch it reliably at the very earliest stage” (the benefits and harms of screening were covered in Vol.6).
② Use medication preventively (risk-reducing medication). Drugs that lower the risk of hormone-receptor-positive breast cancer (such as tamoxifen; details in Vol.15) can be used for prevention. They do not suit everyone and are weighed against age and side effects.
③ Surgery that greatly reduces risk (risk-reducing surgery). This is what the actress at the outset chose. Preventive removal of the breasts is reported to reduce breast cancer risk by roughly 90–95%. Removal of the ovaries and fallopian tubes (risk-reducing salpingo-oophorectomy) not only sharply lowers ovarian cancer risk but has also been linked to improved survival in BRCA carriers. At the same time, surgery is a major decision—physically and psychologically—carrying effects on appearance, hormones, and fertility.
What I want to stress here is that there is no single “right” choice. Even with the same BRCA-positive result, the best road shifts with age, the wish to bear children, family circumstances, and values. Someone in their thirties who hopes to give birth and someone already past menopause will, reasonably, walk the same map of probability differently. What matters is to choose—neither pressured into deciding nor averting one’s eyes and delaying—the “best for me,” taking time, together with specialists. Risk-reducing surgery is not “inevitably someday” but a question of “when and what, within the design of my own life.”
In practice, these options are often not “one or the other” but combined along a timeline. One might watch carefully with intensified screening until childbearing is complete, consider surgery on the ovaries and fallopian tubes once life stage shifts, and take still more time to think about the breasts—acting in stages as the seasons of life change. Because ovarian cancer is hard to catch early and lacks an established effective screening test, surgery on the ovaries and tubes tends to be recommended earlier; the breasts, by contrast, have a high-quality screening alternative, leaving more room to choose unhurried. This reality—that “the circumstances differ by organ”—can be mapped onto your own situation only through dialogue with specialists. Decision-making is not a one-time fork but a long conversation, updated alongside life itself.
The Impact on Family—This Is Not Yours Alone
Hereditary risk has one face that decisively distinguishes it from other cancers: the result concerns your family too. A pathogenic BRCA variant is passed to a child with a 50% chance. If you are positive, the option of testing arises for your siblings and children as well (this is called “cascade testing”).
This is a burden and a hope at once. Because you know, a family member who has not yet developed cancer can intensify screening early, or fold it into their life planning. One person’s result enables the whole family to “get ahead” of the disease. On the other hand, “should I tell my children,” “when and how,” are delicate questions with no single right answer. Realistically, proceed in consultation with a genetic counselor, attuned to family members’ ages and relationships.
Cascade testing carries difficulties distinct from being tested alone. First, the very act of sharing a result confronts a relative with a weighty choice—to know, or to remain unknowing; some family members will decide they would rather not know, and that wish, too, deserves respect. Second, there is wisdom in the order in which testing begins within a family. Ideally, a close relative who has already developed cancer is tested first, and only once a pathogenic variant is confirmed in that person do unaffected relatives test for that “specific change.” Done this way, a negative result in an unaffected relative carries the firm meaning of “you did not inherit the family’s risk” (the point raised in Branch Point 4). The realities—an affected relative who has already died, or who declines testing—do occur, and they change the insurance coverage and the testing strategy. Genetic testing across a family is, as much as it is medicine, a matter of communication and of building consensus.
The handling of minor children deserves particular care. Preventive options around BRCA generally become meaningful only in adulthood, and there is usually no need to rush testing in childhood. The realistic stance, then, is not to “load it all on them now” but to prepare so that the necessary information can be handed over when they are old enough to face it as a choice of their own life. Men, too, are not exempt. A male BRCA carrier not only faces a slightly raised risk of breast and prostate cancer but also serves as a “bridge,” able to pass the same change to daughters and sons with equal probability. The assumption that “this is a women’s issue only” is another one to let go of here.
To worried family members, I would say this: genetic risk is not a “curse” but a “map.” With a map, you can choose your road. And that map is not something to carry alone—it can be shared within a family, each person facing it at their own pace.
Concern about disadvantage in insurance or employment on the basis of genetic information (genetic discrimination) is entirely understandable. Legal protections differ by country, and pre-test counseling sorts through these social dimensions as well.
What Comes Next—Another Kind of Risk, Told by Images
So far, this has been about risk assessment that “reads the genes.” But in recent years, a wholly different angle on estimating risk has been maturing: an approach that has AI read the images themselves—mammograms and the like—to predict future risk. Without examining any gene, a “hint” of future risk lies hidden within image information such as breast density and pattern, and AI has begun to read it beyond what the human eye can. The genetic risk map and the image-derived risk map: when the two overlap, risk assessment grows still more precise. Image-derived AI risk models will be taken up head-on in Vol.13, on the refinement of diagnosis.
And next time, Vol.11 shifts the lens from “risk” to “living.” Balancing treatment with work, questions of money, how to tell family, partners, and children, appearance care and fertility preservation, and living alongside the fear of recurrence—it moves toward the close of Part 2, “how to keep living a life” that lies beyond diagnosis and preventive choice. After reading the map of probability, what awaits is, after all, each person’s own irreplaceable daily life.
My Thought
When talking about genetic testing, the misunderstanding I most want to dispel is the belief that “positive equals certain cancer.” A BRCA-positive result is a “probability”—being born with a constitution poor at repair—not a sentence. If anything, a person found to be high-risk holds more cards than someone who knows nothing: intensified screening, preventive medication, and risk-reducing surgery—means of getting ahead of the future. Those who hold a map can choose their road.
To add an expert lens: the frontier of this field is shifting, quietly but decisively, from a binary “yes/no” toward a continuum of “how much.” Multigene panels make moderate-risk genes visible, polygenic risk scores sum countless tiny differences, and image-derived AI models add information independent of genetics. Integrate these, and an individualized prediction—”your risk over the next ten years falls in this range”—gains real plausibility. But the challenges must be stated frankly. While genes that raise risk are found one after another, the practical guidance of “then at what age, which intervention, for whom” is still developing. The interpretation of VUS, the handling of moderate risk, and social preparedness against genetic discrimination—the pattern of technology racing ahead while operation and ethics chase it is a microcosm of precision medicine as a whole. The map has grown precise. What is asked next is a maturity on the human side: how to use that map, and how to support one another with it.
Continue the Series
- Vol.1: Breast Cancer Is Not One Disease (the series’ entry point)
- Previous: Vol.9 | From the Day You Were Told
- Next: Vol.11 | Building Treatment Into a Life
Related Reading
If you leave a comment telling us which cancers or conditions you’d like us to cover next, we’ll prioritize them in future features.
Comments